Resverlogix Corp. (TSE:RVX – Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 5250 shares changing hands. The stock had previously closed at C$0.06.
Resverlogix Price Performance
The stock has a market cap of C$14.97 million, a price-to-earnings ratio of -1.10 and a beta of 0.78. The firm’s fifty day moving average price is C$0.06 and its two-hundred day moving average price is C$0.07.
Resverlogix Company Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than Resverlogix
- What is MarketRank™? How to Use it
- 3 Stocks With Unusual Call Option Activity
- What Is Dividend Yield and How Do You Calculate It?
- Trump Media & Technology Group Soars on Market Debut
- 3 Healthcare Dividend Stocks to Buy
- 3 Stocks Insiders Are Buying That Analysts Love
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
